Published in Ann Neurol on March 01, 1996
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov (2010) 5.55
Interferon beta in multiple sclerosis. BMJ (1996) 3.80
The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain (2010) 3.48
Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ (2003) 3.31
Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ (1999) 2.66
Evidence for a two-stage disability progression in multiple sclerosis. Brain (2010) 2.63
Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry (2000) 2.01
Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology (2011) 1.89
COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol (2006) 1.87
A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler (2012) 1.74
A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med (2011) 1.65
Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry (2002) 1.64
"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (1998) 1.56
Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol (2010) 1.54
Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology (2012) 1.53
Impact of specialty drugs on the use of other medical services. Am J Manag Care (2008) 1.51
Pediatric multiple sclerosis. Nat Rev Neurol (2009) 1.50
Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol (2005) 1.50
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry (1997) 1.44
Placebo effects: clinical aspects and neurobiology. Brain (2008) 1.42
Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest (2005) 1.41
Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence (2011) 1.41
Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci (2007) 1.39
Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord (2010) 1.34
Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord (2012) 1.31
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler (2014) 1.23
Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. BMC Neurol (2010) 1.22
Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol (2009) 1.18
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol (2014) 1.18
Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b. J Clin Invest (1997) 1.15
Placebo? no thanks, it might be bad for me! Eur J Clin Pharmacol (2012) 1.13
Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol (2016) 1.12
An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects. BMC Neurol (2011) 1.11
Assessing depressive symptoms in multiple sclerosis: is it necessary to omit items from the original Beck Depression Inventory? J Behav Med (1999) 1.10
Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry (2000) 1.10
Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry (2000) 1.10
Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates. J Neurol (2007) 1.08
A replicated prospective investigation of life stress, coping, and depressive symptoms in multiple sclerosis. J Behav Med (1997) 1.08
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol (2013) 1.06
One year changes in disability in multiple sclerosis: neurological examination compared with patient self report. J Neurol Neurosurg Psychiatry (2003) 1.06
Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol (2008) 1.05
The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%? Neurology (2009) 1.05
Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol (2014) 1.04
Cytokines and myelination in the central nervous system. ScientificWorldJournal (2008) 1.04
Interferon-beta for treatment of rheumatoid arthritis? Arthritis Res (2002) 1.04
Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler (2008) 1.04
Defining and scoring response to IFN-β in multiple sclerosis. Nat Rev Neurol (2013) 1.04
Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front Neurol (2012) 1.03
Drug treatment of multiple sclerosis. BMJ (2000) 1.02
Therapeutic strategies in childhood multiple sclerosis. Ther Adv Neurol Disord (2010) 1.01
Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry (2004) 1.01
Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol (2014) 1.00
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study. J Neurol (2013) 0.99
Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (1996) 0.99
Immunomodulatory treatment strategies in multiple sclerosis. J Neurol (2008) 0.99
Treatment of multiple sclerosis: current concepts and future perspectives. J Neurol (2011) 0.98
GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology (2009) 0.98
The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: Design and baseline characteristics. Mult Scler Relat Disord (2012) 0.97
Assessing treatment response to interferon-β: is there a role for MRI? Neurology (2013) 0.97
History of modern multiple sclerosis therapy. J Neurol (2005) 0.96
Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort. BMC Neurol (2010) 0.96
Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLoS One (2014) 0.96
Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis. Prostaglandins Leukot Essent Fatty Acids (2009) 0.96
Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry (2002) 0.96
Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol (2005) 0.96
Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis. PLoS One (2011) 0.96
Disease-modifying agents in multiple sclerosis. Ann Indian Acad Neurol (2009) 0.95
Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol (2005) 0.95
An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations. Patient Prefer Adherence (2015) 0.94
Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One (2013) 0.94
MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study. Eur Radiol (2009) 0.94
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. J Neurol (2013) 0.94
A herpes simplex virus-derived replicative vector expressing LIF limits experimental demyelinating disease and modulates autoimmunity. PLoS One (2013) 0.94
Recent Advances. Neurology. BMJ (1999) 0.93
Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America. Ther Adv Neurol Disord (2011) 0.92
Current and future therapies for multiple sclerosis. Scientifica (Cairo) (2013) 0.92
Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One (2011) 0.92
New approaches in the management of multiple sclerosis. Drug Des Devel Ther (2010) 0.92
Estimating time-to-event from longitudinal ordinal data using random-effects Markov models: application to multiple sclerosis progression. Biostatistics (2008) 0.92
Chronotherapy using corticosteroids for multiple sclerosis relapses. J Neurol Neurosurg Psychiatry (2006) 0.92
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics (2013) 0.92
Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo. Proc Natl Acad Sci U S A (2013) 0.92
Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis. J Biol Chem (2011) 0.92
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurol (2014) 0.91
Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland. Patient Prefer Adherence (2012) 0.91
Patient perceptions of multiple sclerosis and its treatment. Patient Prefer Adherence (2012) 0.91
Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate. Drug Des Devel Ther (2014) 0.90
Overexpression of SIRT1 protein in neurons protects against experimental autoimmune encephalomyelitis through activation of multiple SIRT1 targets. J Immunol (2013) 0.90
Toll-like receptors in multiple sclerosis. Curr Top Microbiol Immunol (2009) 0.90
Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand (2010) 0.90
Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. Neurol Sci (2007) 0.90
Interferon beta and glatiramer acetate therapy. Neurotherapeutics (2013) 0.90
Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells. BMC Med Genomics (2009) 0.89
Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of multiple sclerosis. ACS Chem Neurosci (2011) 0.89
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. J Neurol (2007) 0.89
The functional independence measure: a new tool for rehabilitation. Adv Clin Rehabil (1987) 4.86
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum (2001) 4.60
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med (2000) 4.50
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Interrater reliability of the 7-level functional independence measure (FIM) Scand J Rehabil Med (1994) 3.86
The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler (1999) 3.71
The reliability of the functional independence measure: a quantitative review. Arch Phys Med Rehabil (1996) 3.41
The structure and stability of the Functional Independence Measure. Arch Phys Med Rehabil (1994) 3.30
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy. N Engl J Med (1972) 3.09
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol (1995) 3.06
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet (1996) 2.98
The Functional Independence Measure: tests of scaling assumptions, structure, and reliability across 20 diverse impairment categories. Arch Phys Med Rehabil (1996) 2.86
Light and electron microscopic observations on Rosenthal fibers in Alexander's disease and in multiple sclerosis. J Neuropathol Exp Neurol (1970) 2.85
Stroke rehabilitation: analysis of repeated Barthel index measures. Arch Phys Med Rehabil (1979) 2.64
Frontal lobe injuries, violence, and aggression: a report of the Vietnam Head Injury Study. Neurology (1996) 2.55
Cellular differentiation of the immune system of mice. I. Separate splenic antigen-sensitive units for different types of anti-sheep antibody-forming cells. J Exp Med (1968) 2.51
"Economy class" stroke syndrome? Neurology (2002) 2.24
Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens. J Immunol (1984) 2.21
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology (1998) 2.16
Outcome of comprehensive medical rehabilitation: measurement by PULSES profile and the Barthel Index. Arch Phys Med Rehabil (1979) 2.14
Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry (2002) 2.08
Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol (1991) 2.08
Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol (1998) 1.97
Effectiveness of assistive technology and environmental interventions in maintaining independence and reducing home care costs for the frail elderly. A randomized controlled trial. Arch Fam Med (1999) 1.94
Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood (2000) 1.90
Etiology of progressive multifocal leukoencephalopathy. Identification of papovavirus. N Engl J Med (1973) 1.90
Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary-care hospitals. Stroke (1997) 1.89
NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology (2010) 1.88
A case-mix classification system for medical rehabilitation. Med Care (1994) 1.84
Viral infections and demyelinating diseases. N Engl J Med (1973) 1.84
Overview of azathioprine treatment in multiple sclerosis. Lancet (1991) 1.83
Eight-year follow-up study of brain atrophy in patients with MS. Neurology (2002) 1.78
Glutamic acid: selective depletion by viral induced granule cell loss in hamster cerebellum. Brain Res (1974) 1.77
Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol (1996) 1.76
Functional status measures in a comprehensive stroke care program. Arch Phys Med Rehabil (1977) 1.76
Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology (2012) 1.76
Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem (1999) 1.73
Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol (2000) 1.71
Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J Virol (1998) 1.70
Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol (1999) 1.69
Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol (1997) 1.66
Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol (2001) 1.66
Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res (1988) 1.66
Syndromes of amyotrophic lateral sclerosis and dementia: relation to transmissible Creutzfeldt-Jakob disease. Ann Neurol (1983) 1.65
In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology (2009) 1.64
Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum Mol Genet (1998) 1.63
Correlates of posttraumatic epilepsy 35 years following combat brain injury. Neurology (2010) 1.62
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology (2002) 1.61
White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. AJNR Am J Neuroradiol (1998) 1.59
Increased tissue damage and lesion volumes in African Americans with multiple sclerosis. Neurology (2010) 1.58
Epilepsy after penetrating head injury. I. Clinical correlates: a report of the Vietnam Head Injury Study. Neurology (1985) 1.57
A twin MRI study of size variations in human brain. J Cogn Neurosci (2000) 1.57
Intrauterine growth retardation and risk of sudden infant death syndrome (SIDS) Am J Epidemiol (1989) 1.56
Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol (1997) 1.55
Multiple sclerosis. The spectrum of severity. Arch Neurol (1983) 1.54
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology (2001) 1.53
A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology (1998) 1.52
Diet and alcohol consumption and lung cancer risk in the New York State Cohort (United States) Cancer Causes Control (1997) 1.51
A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler (1999) 1.50